Trial · NCT05705193
Registered outcomes13
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 13 of 13
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Treatment Acceptability/Adherence Scale (TAAS) | The investigators will evaluate TAAS Total Score at the outset of treatment (expected/anticipated acceptability and adherence) and at post-treatment (6 weeks) | Treatment acceptability and adherence as measured by the TAAS Total Score; higher scores on this self-report measure indicate greater treatment acceptability and adherence |
| Primary | Credibility/Expectancy Questionnaire (CEQ) | The investigators will evaluate CEQ Total Score at the outset of treatment (to assess initial perceptions of treatment credibility) and at post-treatment (6 weeks) | Treatment credibility and expectancy as measured by the CEQ Total Score; higher scores on this self-report measure indicate greater treatment credibility and expectancy |
| Primary | System Usability Scale (SUS) | The investigators will evaluate SUS Total Score at the outset of treatment (to assess initial perceptions of treatment usability) and at post-treatment (6 weeks) | Usability of the intervention as measured by the SUS Total Score; higher scores on this self-report measure indicate greater perceived usability |
| Primary | Feasibility (proportion of subjects who agree to participate in the offered treatment, complete assigned exercises, and complete the entire treatment regimen) | Our feasibility criteria will be assessed by calculating percentages at the conclusion of the study | Feasibility will be assessed according to the following criteria: 1) at least 80% of eligible subjects offered the treatment agree to participate; 2) subjects will complete at least 80% of assigned treatment exercises; 3) at least 80% of participants who start the treatment will finish it. |
| Secondary | Trail Making Test Part B | The investigators will evaluate change in time (seconds) to complete the Trail Making Test Part B at post-treatment (6 weeks) relative to pre-treatment (baseline) | Set-shifting abilities as measured by time to complete the Trail Making Test Part B in seconds; lower scores indicate better set-shifting performance |
| Secondary | Montgomery-Asberg Depression Scale (MADRS) | The investigators will evaluate change in Total MADRS Score at post-treatment (6 weeks) relative to pre-treatment (baseline) | Depressive symptoms as measured by the Total MADRS Score; lower scores indicate less depressive symptoms |
| Secondary | World Health Organization Disability Assessment Schedule (WHODAS) | The investigators will evaluate change in Total WHODAS Score at post-treatment (6 weeks) relative to pre-treatment (baseline) | Functional disability as measured by the Total WHODAS Score; lower scores indicate less functional disability |
| Secondary | Everyday Cognition (ECog) | The investigators will evaluate change in Total ECog Score at post-treatment (6 weeks) relative to pre-treatment (baseline) | Subjective cognitive concerns as measured by the Total ECog Score; lower scores indicate less subjective cognitive concern |
| Secondary | Verbal Fluency | The investigators will evaluate change in total number of words produced at post-treatment (6 weeks) relative to pre-treatment (baseline) | Verbal generativity as measured by the total number of words produced according to pre-specified rules; higher scores indicate better verbal generativity performance |
| Secondary | Stroop Color and Word Test | The investigators will evaluate change in total correct responses at post-treatment (6 weeks) relative to pre-treatment (baseline) | Inhibitory control as measured by total correct responses on the inhibition condition of the Stroop Test; higher scores indicate better inhibitory control performance |
| Secondary | Fatigue Assessment Scale (FAS) | The investigators will evaluate change in total FAS Score at post-treatment (6 weeks) relative to pre-treatment (baseline) | Fatigue as measured by the Total FAS Score; lower scores indicate less fatigue |
| Secondary | California Verbal Learning Test (CVLT) | The investigators will evaluate change in long delayed free recall at post-treatment (6 weeks) relative to pre-treatment (baseline) | Verbal memory as measured by the total number of words correctly recalled on the long delayed free recall trial; higher scores indicate better episodic memory performance |
| Secondary | Short Physical Performance Battery (SPPB) | The investigators will evaluate change in physical performance at post-treatment (6 weeks) relative to pre-treatment (baseline) | Physical performance as measured by the Total SPPB Score; higher scores indicate better physical performance. |
Source ClinicalTrials.govtrials-2026-11-12-0.4.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNone stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT05705193/registered